Kronos Bio

First-in-class therapies against historically intractable targets

Lanraplenib Clin1 AML; 3+ undisclosed programs RD undisclosed; Entospletinib Clin3 (discontinued Nov 2022) AML

Kronos Bio is developing therapeutics that target dysregulated transcription that underpins most human diseases. Individual transcription factors, which dictate expression of a subset of genes, have been attractive drug targets but have achieved little success. Instead, Kronos is analyzing the total transcriptional regulatory network (TRNs) of diseased cells to identify critical nodes responsible for a transcription factor's activity. This approach circumvents the need to focus on a single transcription factor and offers many avenues to target. Kronos has identified three investigational compounds that are being investigated in cancer patients. This includes two oral SYK inhibitors. SYK is a critical node in the dysregulated TRN of acute myeloid leukemia.

Jobs: